Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway

Blood

Volumn 92, Issue 1, 1998, Pages 241-251

  Xu, Feng Hao ^b   Sharma, Sanjesh ^b   Gardner, Agnes ^b   Tu, Yiping ^b   Raitano, Arthur ^b   Sawyers, Charles ^b   Lichtenstein, Alan ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FAS ANTIGEN; INTERLEUKIN 6; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ARTICLE; CELL VIABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSACTIVATION;

EID: 0032125757     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.1.241.413k28_241_251     Document Type: Article

References (54)

1. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 84:3063, 1994
2. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J: Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 162:248, 1995
3. Anderson K, Jones RM, Morimoto C, Leavitt P, Barut BA: Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 73:1915, 1989
4. Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth J, Anderson K: Role of interleukin 6 in the growth of myeloma-derived cell lines. Leukemia Res 16:951, 1992
5. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T: The essential role of B cell stimulating factor 2 for the terminal differentian of B cells. J Exp Med 167:332, 1988
6. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of cytokines and gp 130. Blood 86:1243, 1995
7. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326, 1995
8. Graves JD, Draves KE, Craxton A, Saklatvala J, Krebs EG, Clark EA: Involvement of stress activated protein kinase and p38 mitogen- activated protein Kinase in mIgM-induced apoptosis of human B lymphocytes. Proc Natl Acad Sci USA 93:13814, 1996
9. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y: Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 275:90, 1997
10. Johnson N, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL: Signal transduction pathways regulated by mitogen activated extracellular response kinase kinase kinase induce cell death. J Biol Chem 271:3229, 1996
11. Wilson DJ, Fortner KA, Lynch DH, Mattingly RR, Macara IG, Posada JA, Budd RC: JNK, but not MAPK, activation is associated with fas-mediated apoptosis in human T cells. Eur J Immunol 26:989, 1996
12. Marshall CJ: Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179, 1995
13. Hill CS, Treisman R: Transcriptional regulation by extracellular signals: Mechanisms and specificity. Cell 80:199, 1995
14. Derijard B, Hibi M, Wu I-H, Barrett T, Su B, Karin M, Davis R: JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:11025, 1994
15. Kyriakis JM, Benerjee P, Nikolakaki P, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgert JR: The stress-activated protein kinase subfamily of c-jun kinases. Nature 369:156, 1994
16. Minden A, Lin A, McMahon M, Lange-carter C, Derijard B, Davis RJ, Johgnson G, Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266:1719, 1994
17. Lange-Carter CA, Johnson GL: Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science 265:1458, 1994
18. Gupta S, Campbell D, Derijard B, Davis RJ: Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389, 1995
19. Hibi M, Lin A, Smeal T, Minden A, Karin M: Identification of an oncoprotein and UV responsive protein kinase that binds and potentiatesthe c-jun activation domain. Genes Dev 7:2135, 1993
20. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Interleukin-6 inhibits fasinduced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89:227, 1997
21. Minden A, Lin A, Smeal T, Derijard B, Cobb M, Davis R, Karin M: cjun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol 14:6683, 1994
22. Wang H-G, Millan JA, Cox AD, Der CJ, Rapp UR, Beck T, Zha H, Reed JC: R-ras promotes apoptosis caused by growth factor deprivation via a BCL-2 suppressible mechanism. J Cell Biol 129:1103, 1995
23. Raitano A, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene activates jun kinase and requires jun for transformation. Proc Natl Acad Sci USA 92:11746, 1995
24. Levy N, Yonish-Rouach E, Oren M, Kimchi A: Complementation by wild type p53 of interleukin-6 effects on M1 cells: Induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 13:7942, 1993
25. Belizario JE, Dinarello CA: Interleukin 1, interleukin 6, tumor necrosis factor and transforming growth factor-beta increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res 51:2379, 1991
26. Daeipour M, Kumar G, Amaral MC, Nel AE: Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in the IL-6 responsive B cell line AF-10. J Immunol 150:4743, 1993
27. Kumar G, Gupta S, Wang S, Nel AE: Involvement of janus kinases, p52shc, Raf-1 and MEK-1 in the IL-6-induced mitogen-activated protein kinase cascade of a growth-responsive B cell line. J Immunol 153:4436, 1994
28. Angel P, Imagawa M, Chiu R, Stein, B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M: Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 49:729, 1987
29. Liu Z, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell 87:565, 1996
30. Lenczowski JM, Dominguez L, Eder AM, King LB, Zacharchuk CM, Ashwell JD: Lack of a role for jun kinase and AP 1 in fas-induced apoptosis. Mol Cell Biol 17:170, 1997
31. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN; Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380:75, 1996
32. Goulot E, Raingeaud J, Ranger A, Tepper RI, Davis RJ, Harlow E, Sanchez I: Mitogen-activated protein kinase-mediated fas apoptotic signaling pathway. Proc Natl Acad Sci USA 94:3302, 1997
33. Estus S, Zaks WJ, Freeman RS, Gruda M, Bravo R, Johnson EM: Altered gene expression in neurons during programmed cell death: Identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 127:1717, 1994
34. Ham J, Babji C, Whitfield J, Pfarr CM, Lallemand D, Yaniv M, Rubin LL: A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927, 1995
35. Sawai H, Okazaki T, Yamamoto H, Okano H, Takeda Y, Tashima M, Sawada H, Okuma M, Ishikura H, Umehara H, Domae N: Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 270:27326, 1995
36. Collata F, Polentarutti N, Sironi M, Mantovani A: Expression and involvement of c-fos and c-jun proto-oncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 267:18278, 1992
37. Rezzonico R, Loubat A, Lallemand D, Pfarr CM, Far DF, Proudfoot A, Rossi B, Ponzio G: Cyclic AMP stimulates a junD/Fra-2 AP-1 complex and inhibits the proliferation of IL-6-dependent cell lines. Oncogene 11:1069, 1995
38. Martin SJ: Apoptosis: Suicide, execution or murder? Trends Cell Biol 3:141, 1993
39. Nagata S, Golstein P: The fas death factor. Science 267:1449, 1995
40. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF: CD40 expression in malignant plasma cells. J Immunol 152:117, 1994
41. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC: CD40 ligand triggered IL-6 secretion in multiple myeloma. Blood 85:1903, 1995
42. Chen Y-R, Wang X, Templeton D, Davis RJ, Tan T-H: The role of c-jun N-terminal kinase in apoptosis induced by ultraviolet C and gamma radiation. J Biol Chem 271:31929, 1996
43. Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson K: Blockade of mitogen-activated protein kinase cascade signaling in IL-6-independent multiple myeloma cells. Clin Cane Res 3:1017, 1997
44. Liu, P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van Ness B: Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology group phase III trial. Blood 88:2699, 1996
45. Billadeau D, Liu P, Jelinek D, Shah N, LeBien T, Van Ness B: Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6. Cancer Res 57:2268, 1997
46. Ishizuka T, Sakata N, Johnson GL, Gelfand EW, Terada N: Rapamycin potentiates dexamethasone-induced apoptosis and inhibits JNK activity in lymphoblastoid cells. Biochem Biophys Res Comm 230:386, 1997
47. Anderson K: Interleuklin-6 related regulation of growth and apoptosis of myeloma cells. Proceedings of the VI International workshop on multiple myeloma. Boston, MA, June 1997
48. Kanatani Y, Kasukabe T, Okabe-Kado J, Hayashi S, Yamamoto-Yamaguchi Y, Motoyoshi K, Nagata N, Honma Y: Transforming growth factor beta and dexamethasone cooperatively enhance c-jun gene expression and inhibit the growth of monocytoid leukemia cells. Cell Growth Diff 7:187, 1996
49. Sikora E, Grassilli E, Radziszewska E, Bellesia E, Barbieri D, Franceschi C: Transcription factors DNA-binding activity in rat thymocytes undergoing apoptosis after heat-shock or dexamethasone treatment. Biochem Biophys Res Comm 197:709, 1993
50. Goldstone SD, Lavin MF: Prolonged expression of c-jun and associated activity of the transcription factor AP-1, during apoptosis in a human leukemic cell line. Oncogene 9:2305, 1994
51. Tu Y, Renner S, Xu F-H, Fleishman A, Taylor J, Weisz J, Vescio R. Rettig M, Berenson J, Krajewski S, Reed JC, Lichtenstein A: BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 58:256, 1998
52. Schwarze MMK, Hawley RG: Prevention of myeloma cell apoptosis by ectopic BCL-expression or interleukin-6 mediated upregulation of BCL-X-L. Cancer Res 55:2262, 1995
53. Lotem J, Sachs L: Regulation of BCL-2, BCL-X and BAX in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Growth Differ 6:647, 1995
54. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ: Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL. Cell 87:619, 1996